A Within-Subject Comparison of 6-[18F]Fluoro-m-tyrosine and 6-[18F]Fluoro-L-dopa in Parkinson’s Disease

Catherine L. Gallagher, MD1,2,*, Bradley T. Christian, PhD3,4, James E. Holden, PhD3, Onofre T. Dejesus, PhD5, Robert J. Nickles, PhD3, Laura Buyan-Dent, MD, PhD2, Barbara B. Bendlin, PhD5,6, Sandra J. Harding, MS5,6, Charles K. Stone, MD6, Barb Mueller, BS4, and Sterling C. Johnson, PhD5,6

1William S. Middleton Veterans Hospital, Madison, Wisconsin, USA
2Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
3University of Wisconsin, Department of Medical Physics, Madison, Wisconsin, USA
4Waisman Laboratory for Brain Imaging and Behavior, Madison, Wisconsin, USA
5William S. Middleton Veterans Hospital G.R.E.C.C., Madison, Wisconsin, USA
6Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA

Abstract

Progression of Parkinson’s disease symptoms is imperfectly correlated with positron emission tomography biomarkers for dopamine biosynthetic pathways. The radiopharmaceutical 6-[18F]fluoro-m-tyrosine is not a substrate for catechol-O-methyltransferase and therefore has a more favorable uptake-to-background ratio than 6-[18F]fluoro-L-dopa. The objective of this study was to evaluate 6-[18F]fluoro-m-tyrosine relative to 6-[18F]fluoro-L-dopa with partial catechol-O-methyltransferase inhibition as a biomarker for clinical status in Parkinson’s disease. Twelve patients with early-stage Parkinson’s disease, off medication, underwent Unified Parkinson Disease Rating Scale scoring, brain magnetic resonance imaging, and 3-dimensional dynamic positron emission tomography using equivalent doses of 6-[18F]fluoro-m-tyrosine and 6-[18F]fluoro-L-dopa with tolcapone, a catechol-O-methyltransferase inhibitor. Images were realigned within subject, after which the tissue-derived uptake rate constant was generated for volumes of interest encompassing the caudate nucleus, putamen, and subregions of the putamen. We computed both bivariate (Pearson) and partial (covariate of age) correlations between clinical subscores and tissue-derived uptake rate constant. Tissue-derived uptake rate constant values were correlated between the radiopharmaceuticals (r = 0.8). Motor subscores were inversely correlated with the contralateral putamen 6-[18F]fluoro-m-tyrosine tissue-derived uptake rate constant (|r| > 0.72, P < .005) but not significantly with the 6-[18F]fluoro-L-dopa tissue-derived uptake rate constant. The uptake rate constants for both radiopharmaceuticals were also inversely correlated with activities of daily living subscores, but the magnitude of correlation coefficients was greater for 6-[18F]fluoro-m-tyrosine. In this design, 6-[18F]fluoro-m-tyrosine uptake better reflected clinical status than did 6-[18F]fluoro-L-dopa uptake. We attribute this finding to 6-[18F]fluoro-m-...
tyrosine’s higher affinity for the target, L-aromatic amino acid decarboxylase, and the absence of other major determinants of the uptake rate constant. These results also imply that L-aromatic amino acid decarboxylase activity is a major determinant of clinical status.

**Keywords**

positron emission tomography; Parkinson’s disease/radionuclide imaging; dopamine/metabolism

Specific uptake of radiopharmaceutical agents such as [18F]fluoro-L-dopa (FDOPA) that target central dopamine biosynthetic pathways have been used as surrogate outcome measures in Parkinson’s disease (PD) clinical trials. However, longitudinal changes in striatal uptake of FDOPA, imaged using positron emission tomography (PET), do not correlate optimally with clinical measures of disease progression. Furthermore, kinetic modeling of FDOPA uptake is complicated by variability in its rate of loss and by its COMT metabolite, 3-O-methyl-FDOPA (3OMD), which crosses the blood–brain barrier to reduce signal to background. Another radiotracer that targets L-aromatic amino acid decarboxylase (AADC) 6-[18F]fluoro-m-tyrosine (FMT) offers advantages over FDOPA in that it has higher affinity for the target and is not a substrate for catechol-O-methyltransferase (COMT). FMT PET has been used widely in nonhuman primate models of PD but infrequently in human studies. In the past, dosimetry data from studies in which carbidopa pretreatment was not used have limited the dose of FMT to 2.5 mCi to keep bladder wall exposure under 5 rads. Although some previous studies have used 5 mCi of FMT in humans, others have used 2.5 mCi. The primary goal of this study was to validate the performance of FMT as a correlate of clinical symptoms in PD. A secondary goal was to investigate comparative bladder wall radiation dosimetry for FDOPA and FMT in this study population.

**Patients and Methods**

Twelve subjects (mean age, 61 years; SD, 9.3 years; 10 men) with Hoehn and Yahr stages 1–3 idiopathic Parkinson’s disease (PD) by UK Brain Bank criteria, normal liver function, and the absence of other major disease were recruited from local movement disorders clinics. Of these subjects, 5 were taking monoamine oxidase inhibitors (MAOIs), 7 were taking dopamine agonists (pramipexole or ropinerole), and 3 were taking carbidopa/levodopa (750–1200 mg of levodopa daily). Procedures included brain FDOPA and FMT PET imaging, magnetic resonance imaging (MRI), and Unified Parkinson Disease Rating Scale (UPDRS) scoring by a movement disorders specialist (C.G.). Subjects were off antiparkinson medication for 18 hours prior to PET and UPDRS scoring. The local institutional review board approved the protocol; informed consent was obtained from all participants.

For PET imaging, subjects were pretreated with carbidopa, 2.5 mg/kg orally, and tolcapone (a COMT inhibitor), 200 mg, before the FDOPA scan. These pretreatment doses were given a mean of 59 minutes (range, 47–75 minutes; SD, 9 minutes) before the FDOPA scan and 65 minutes (range, 50–74 minutes; SD, 7 minutes) before the FMT scan. Because tolcapone has in rare cases been associated with liver damage, serum AST, an index of liver function, was acquired at study enrollment and 2–4 weeks after the tolcapone dose. Potential subjects with abnormal baseline AST were excluded from the study.

FDOPA and FMT were synthesized by electrophilic fluorination of the appropriate stannylated precursors (for FMT, N-[trifluoroacetyl]-3-acetoxy-6-[trimethylstannyl]-l-phenylalanine ethyl ester; ABX, Radeberg, Germany) followed by flash chromatography.
over alumina, hydrolysis in HBr, separation by semiprep HPLC, and a final workup to radiopharmaceutical purity.\textsuperscript{15,16}

PET images were obtained on a Siemens ECAT EXACT HR+ PET scanner with an axial intrinsic resolution of 4.7 mm. Following intravenous injection of 5.2 mCi ± 10\% of radiopharmaceutical, 18 three-dimensional dynamic frames were acquired over 90 minutes. The injected activity of FMT was within 5\% of FDOPA injected activity (mean difference in injected doses was 0.6\%). The mean interval between FMT and FDOPA PET scans was 35 days. During both the FDOPA and the FMT scans, urine was collected 95 and 185 minutes after injection.

MRI scans were obtained on a 3T SIGNA scanner using an 8-channel head coil, with higher-order shimming; a T1-weighted rapid gradient echo volume (MPRAGE; TR, 6.6 ms; TE, 2.8 ms; 166 1.2-mm axial slices) was used for coregistration to PET.

For image analysis, FDOPA and FMT PET sinograms were reconstructed by filtered back-projection into 18 volumes (time frames) of \(128 \times 128 \times 63\), \(1.84 \times 1.84 \times 2.43\) mm voxels, corrected for scatter, attenuation, and F-18 decay. Each frame was realigned within subject to the total sum image of the FDOPA study. The T1-weighted MRI was coregistered to the FDOPA sum image in native space, after which volumes of interest (VOIs), encompassing the caudate nucleus, putamen, and occipital cortex, were defined by single rater (C.G.) on the resampled MRI using in-house software (http://brainimaging.waisman.wisc.edu/~oakes/spam). The putamen was divided along its rostrocaudal axis into anterior, middle, and posterior segments of equal volume. An independent rater (J.H.), who was blind to the clinical status of the research subjects, used the time–activity curves from each volume to derive the normalized tissue uptake rate constant \((K_{\text{occ}})\).\textsuperscript{17} \(K_{\text{occ}}\) values for each VOI were then sorted as ipsilateral or contralateral to the limb manifesting the initial motor symptoms. Bivariate (Pearson) correlations were computed between FMT and FDOPA \(K_{\text{occ}}\) values derived from 8 nonoverlapping subregions and between UPDRS III (motor) subscores and \(K_{\text{occ}}\) values from the contralateral whole putamen, in SPSS (version 16; Chicago, IL). For each tracer, \(K_{\text{occ}}\) values for subregions of the striatum were compared using paired-sample \(t\) tests. Because aging affects UPDRS scores\textsuperscript{18} and possibly FDOPA uptake,\textsuperscript{19} partial correlations with a covariate of age were also computed between UPDRS subscores and regional \(K_{\text{occ}}\) values.

Although more precise methods of calculating bladder wall radiation dose are available,\textsuperscript{20} we made rough estimates of bladder wall exposure based on proportional activity in collected urine by comparison with a previous study of the effect of carbidopa pretreatment on FDOPA dosimetry.\textsuperscript{21} The comparison study, which used similar void times, found that bladder wall exposure reached 68\% of the estimated total exposure of 0.556 rad/mCi prior to the first void. To compare our data, we multiplied decay-corrected urine activity (in \(\mu\)Ci/cc) by urine volume (cc) and then expressed this total bladder content activity as a proportion of injected dose. Bladder wall exposure from FMT was then estimated relative to published FDOPA values as \(0.556\ \text{rad/mCi} \times ([0.68][\text{FMT/FDOPA proportion at void 1}] + [0.32][\text{FMT/FDOPA proportion at void 2}])\).

**Results**

1. A comparison of FDOPA to FMT uptake in 8 nonoverlapping regions (ipsilateral and contralateral caudate nucleus, anterior, middle, and posterior putamen) showed that \(K_{\text{occ}}\) values were correlated between the radiopharmaceuticals \((r = 0.8; \text{Fig. 1A})\), and that the difference between FMT and FDOPA \(K_{\text{occ}}\) values was greater for higher \(K_{\text{occ}}\) values (Fig. 1B).
2. In the presence of tolcapone pretreatment for FDOPA, the radiopharmaceuticals provided a similar range of $K_{occ}$ values (FMT: range, 0.0184; mean, 0.013; SD, 0.005; FDOPA: range, 0.0172; mean, 0.0081; SD, 0.004). FMT displayed slightly better ability to distinguish the earlier from later-affected posterior putamen by the paired $t$ test ($t[df]$, $P; -3.80[11]$, 0.003 for FMT and $-3.25[11]$, 0.008 for FDOPA). Absolute differences in $K_{occ}$ values between the posterior and anterior putamen, left and right putamen, and left and right posterior putamen were each greater for FMT than for FDOPA (paired $t$ test, $P < .03$).

3. Within the striatum, the uptake profile differed in that FMT $K_{occ}$ was maximal in the anterior putamen, whereas FDOPA $K_{occ}$ was similar between the caudate nucleus and anterior putamen (Fig. 2). Mean caudate nucleus/whole putamen $K_{occ}$ ratios (averaged between hemispheres) were 1.37 for FDOPA and 1.10 for FMT; mean anterior/posterior putamen ratios were 3.4 (SD, 2.5) for FDOPA and 2.3 (SD, 0.6) for FMT. The anterior/posterior putamen ratio differed significantly between brain hemispheres for FMT ($P = .015$) but less so for FDOPA ($P = .27$) because of the greater variance in the FDOPA ratio.

4. UPDRS III scores from the initially affected side of the body were inversely correlated with the contralateral putamen FMT $K_{occ}$ ($r = -0.762$, $P < .005$) but not significantly with the FDOPA $K_{occ}$ ($r = -0.512$, $P = .089$); scores for the later affected side of the body were also inversely correlated with the ipsilateral putamen FMT $K_{occ}$ ($r = -0.834$, $P = .001$) but less so with the FDOPA $K_{occ}$ ($r = -0.552$, $P = .063$; Fig. 3). Partial correlations between UPDRS II and UPDRS III and striatal FMT uptake were significant; UPDRS II was also partially correlated with FDOPA uptake, but the magnitude of the correlation coefficients was less (Table 1).

5. Based on data from a pilot study conducted in 13 healthy individuals (mean age, 47 years) during which urine was collected from voids 2 and 3 hours postinjection, we found that FMT metabolites were excreted more rapidly into the urine than were FDOPA metabolites and that fractional excretion declined with age (Dejesus, unpublished). For these controls, the average fraction of administered radioactivity in the bladder at a mean of 107 and 186 minutes postinjection was 39% and 10%, respectively, for FMT, compared with 23% and 31%, respectively, for FDOPA. In the PD subjects, mean fractional excretion at 95 and 185 minutes was 29.5% and 16%, respectively, for FMT and 24.5% and 12%, respectively, for FDOPA with tolcapone. Bladder wall exposure estimates comparing FMT/carbidopa with FDOPA/carbidopa were 0.70 rad/mCi for controls and 0.58 rad/mCi for PD subjects.

6. No subjects showed a delayed elevation of AST after the single dose of tolcapone.

**Discussion**

To our knowledge, this is the first study in human subjects comparing FMT with FDOPA PET. We found that in early PD, the rostrocaudal gradient in uptake differed between the radiopharmaceuticals and that FMT was better correlated with clinical symptoms than FDOPA with incomplete COMT inhibition. Previous FDOPA studies of PD have shown that FDOPA uptake is best preserved in the anterior and ventral portions of the striatum, but is quantitatively similar between the caudate nucleus and anterior putamen. In contrast, we found that FMT uptake in the anterior putamen exceeded that in the caudate nucleus. In young healthy individuals, no anterior–posterior gradient in striatal FDOPA uptake is detectable; with aging, slightly decreased uptake in the putamen relative to the rostral striatum, develops.
The differing rostrocaudal uptake profile between FMT and FDOPA probably reflects biological differences in the trapped metabolites. FDOPA (an analogue of L-dopa) is taken up into catecholaminergic neurons, where it is decarboxylated by AAAD to fluorodopamine, which can be taken up into synaptic vesicles by vesicular monoamine transporter type 2 (VMAT2) and cleared from the synaptic cleft by dopamine transporters (DATs). COMT metabolizes both FDOPA and fluorodopamine to produce 3-O-methyl-fluorodopa (3OMFD) and 3-O-methyl-p-tyramine, respectively. 3OMFD crosses the blood–brain barrier, raising nonspecific background activity in FDOPA scans. Metabolism of fluorodopamine by the outer mitochondrial membrane enzyme monoamine oxidase type A (MAO-A) produces metabolic products 3,4-dihydroxyphenylacetic acid and then homovanillic acid (HVA) via COMT.

3OMFD, in contrast, is not a substrate for COMT and has 10-fold greater affinity for AAAD than does FDOPA. Its AAAD product amine, 6-fluoro-m-tyramine, has 1.5- to 3-fold greater affinity for the monoamine MAO-A than does fluorodopamine, with the resulting product fluoro-m-hydroxy-phenylacetic acid (FHPAA), which is trapped in the striatum. FMT is a poor substrate for DATs and VMAT2 and so is not trapped in synaptic vesicles. Therefore, although FMT trapping reflects primarily AADC and MAO activity, FDOPA trapping also depends on COMT activity and on reuptake and vesicularization, making FDOPA useful for modeling dopamine turnover. Thirty minutes after injection of rats with radiopharmaceutical, 28% of FDOPA has been metabolized by MAO-A and 30% by COMT, whereas 80%–90% of FMT had been metabolized to FHPAA by MAO-A. Postmortem quantitative studies have shown dopamine concentrations in normal caudate nucleus to be 60%–103% that of putamen and concentrations of homovanillic acid (HVA) in the caudate nucleus to be 47%–76% of that in the putamen. Therefore, the moderate difference we observed in rostrocaudal distribution between the radiopharmaceuticals probably reflects the degree to which production of their trapped products depends on MAO-A activity, the normal metabolic byproduct of which, HVA, is of a higher concentration in the putamen.

As a result of this gradient difference, ratios of caudate/putamen and anterior/posterior putamen $K_{occ}$ were lower for FMT, but may prove useful for distinguishing typical from atypical PD due to lower variance. Asselin found that FMT contralateral putamen $K_{occ}$ for 21 Parkinsonian subjects was 50% of that for 3 normal subjects and that the caudate-to-putamen ratio was 1.6, compared with 45% and 1.9, respectively, previously published for FDOPA. The $K_{occ}$ values and caudate nucleus/whole putamen ratios we computed differed slightly based on our VOI selection technique. We expected the higher signal-to-background ratio of FMT to improve our ability to measure disease-related alterations in specific uptake; within the striatum, FMT did produce more significant regional differences, but of a magnitude unlikely to be clinically useful. A within-subject comparison of FMT and FDOPA in a nonhuman primate model of PD concluded that the uptake rate constants were tightly correlated between radiopharmaceuticals and separated healthy from MPTP-lesioned striata equally well, but that variance in FMT $K_{occ}$ values was greater, possibly because the fraction of FMT in plasma is very sensitive to the timing of carbidopa administration. In comparison, we found that the standard deviation in $K_{occ}$ values was similar when comparing FMT to FDOPA with COMT inhibition; this variance was similar in magnitude to that of FMT $K_{occ}$ reported in the lesioned striata of nonhuman primates. We suspect that inhibition of COMT by tolcapone shifted the biochemical properties of FDOPA toward that of a “pure” AAAD agonist (similar to FMT), increasing the mean and range of its $K_{occ}$ values. During FDOPA scans, pretreatment with COMT inhibitors produces marked increases in uptake measures that rely on a tissue reference region, such as $K_{occ}$ and striatal-occipital ratios, in contrast
with those generated using a metabolite-corrected plasma input such as $K_i$.\textsuperscript{34} In a model that assumes irreversible trapping, this uptake rate constant is a ratio of the quantity of tracer ultimately trapped in the striatum relative to its availability (in blood or reference tissue) over time. During FDOPA studies, radioactivity in the reference tissue overestimates the quantity of tracer available for trapping because a portion of the activity is “untrappable” 3OMFD. This metabolite therefore reduces the magnitude of $K_{occ}$ values calculated using a tissue reference.

The primary question raised by this study is why FMT trapping, which follows the physiological pathway of dopamine metabolism less faithfully than FDOPA, better reflected clinical symptoms. Figures 1 and 3 suggest that correlation values were improved by the ability of FMT to spread high $K_{occ}$ values. A number of cross-sectional studies have shown significant correlation between FDOPA uptake and clinical symptoms. Akinesia and rigidity are correlated with lower FDOPA uptake, whereas more severe tremor is associated with preserved uptake in the caudate nucleus relative to the putamen.\textsuperscript{31} In 35 PD subjects off medication, striatal FDOPA $K_{occ}$ was correlated with bradykinesia ($r = -0.64$) and rigidity ($r = -0.59$).\textsuperscript{35} Using $[1^{23}]$ICIT, a dopamine transporter ligand, the correlation of striatal binding with UPDRS II scores was $-0.68$ and with UPDRS III scores was $-0.56$.\textsuperscript{2} Because the magnitude of these correlations is similar to those we found between putamen FDOPA $K_{occ}$ and UPDRS III, the lack of significance of other FDOPA correlations in the present study may simply reflect inadequate statistical power.

Correlations between parkinsonian symptoms and striatal FMT uptake have been investigated in nonhuman primate models. In 14 monkeys lesioned unilaterally with MPTP, the degree of asymmetry in putamen $K_{occ}$ values correlated with the degree of limb tremor asymmetry.\textsuperscript{36} A human study of persons with movement disorders related the pattern of FMT uptake to the clinical subtype, but did not specifically correlate this with clinical scores.\textsuperscript{8} Recently, putaminal infusions of adeno-associated viral type 2 vectors containing the human AADC gene in 10 PD subjects resulted in a dose-dependent increase in FMT uptake and improved UPDRS scores.\textsuperscript{37} In nonhuman primates, similar infusions produced improvement in striatal FMT uptake and clinical scores. Histology confirmed transduction of striatal neurons with medium spiny morphology.\textsuperscript{38} Our results also suggest that residual AADC activity is a major determinant of functional status.

The results of this study suggest that FMT performs well as a biomarker for clinical symptoms in PD. A larger prospective study of PD subjects and normal controls should be done to evaluate the diagnostic sensitivity of FMT and to what degree it reflects clinical changes longitudinally. The urine and AST measurements add information that improves the risk/benefit ratio for using 5-mCi doses of FMT and single 200-mg doses of tolcapone as pretreatment for FDOPA studies in human subjects. Four subjects in this study were being treated with MAO-B inhibitors, which were held for 24 hours prior to PET scanning, but a residual effect of MAO inhibition on FMT uptake cannot be excluded, as the duration of washout is probably weeks.\textsuperscript{39} Measurements of FDOPA metabolites to quantify the effect of 200 mg of tolcapone are also needed.

**Acknowledgments**

Funding agencies: This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Science Research and Development Service and University of Wisconsin Institute for Clinical and Translational Research, funded through a National Institutes of Health Clinical and Translational Science Award (grant number 1UL1RR025011). This work was supported with the use of facilities at the William S. Middleton Memorial Veterans Hospital Geriatric Research Education and Clinical Center and the Waisman Laboratory for Brain Imaging and Behavior, Madison, Wisconsin.
References


  dopa uptake in early Parkinson’s disease: a two-year follow-up study. Mov Disord. 2006;
  3119181]
24. Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular
28. Dejesus OT, Murali D, Nickles RJ. Synthesis of brominated and fluorinated ortho-tyrosine analogs
  in Parkinson’s disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J
33. Doudet DJ, Chan GLY, Jivan S, et al. Evaluation of dopaminergic presynaptic integrity 6-
34. Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-
35. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson’s disease best
36. Eberling JL, Pivirotto P, Bringas J, Bankiewicz KS. Tremor is associated with PET measures of
  [PubMed: 10993693]
37. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy
  primates after gene therapy with AAV-hAADC. Mol Ther. 2006; 14:564–570. [PubMed:
  16829205]
  9710028]
FIG. 1.
A: FMT $K_{occ}$ was plotted against FDOPA $K_{occ}$ for 8 nonoverlapping striatal subregions, yielding a linear (Pearson) correlation coefficient of 0.8. B: FMT $K_{occ}$ was plotted against the difference between FMT $K_{occ}$ and FDOPA $K_{occ}$ for the same subregions.
FIG. 2.
Uptake rate constants ($K_{occ}$) for 8 striatal subregions ipsilateral and contralateral to initial symptoms for FDOPA (left) and FMT (right). Error bars represent 95% confidence intervals; nuc., nucleus; Ant., anterior; Mid., middle; Post., posterior.
FIG. 3.
UPDRS III (motor) subscores from the initially affected (A) and later affected (B) sides of the body versus whole putamen $K_{occ}$ from the opposite brain hemisphere, plotted separately for FMT (triangles) and FDOPA (circles).
**TABLE 1**
Partial correlations between FMT and FDOPA $K_{occ}$ and UPDRS subscores

<table>
<thead>
<tr>
<th>Clinical measure</th>
<th>Brain hemisphere</th>
<th>Structure</th>
<th>FDOPA</th>
<th>FMT</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPDRS II</td>
<td>CL, contralateral to initial motor symptoms</td>
<td>Caudate nucleus</td>
<td>$-0.685^a$</td>
<td>$-0.812^a$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Whole putamen</td>
<td>$-0.702^a$</td>
<td>$-0.819^a$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Posterior putamen</td>
<td>$-0.498$</td>
<td>$-0.723^a$</td>
</tr>
<tr>
<td></td>
<td>IL, ipsilateral to initial motor symptoms</td>
<td>Caudate nucleus</td>
<td>$-0.442$</td>
<td>$-0.686^a$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Putamen</td>
<td>$-0.741^a$</td>
<td>$-0.875^a$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Posterior putamen</td>
<td>$-0.615$</td>
<td>$-0.887^a$</td>
</tr>
<tr>
<td>UPDRS III</td>
<td>CL, contralateral to initial motor symptoms</td>
<td>Caudate nucleus</td>
<td>$-0.239$</td>
<td>$-0.524$</td>
</tr>
<tr>
<td></td>
<td>IL, ipsilateral to initial motor symptoms</td>
<td>Putamen</td>
<td>$-0.437$</td>
<td>$-0.727^a$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Posterior putamen</td>
<td>$-0.213$</td>
<td>$-0.591$</td>
</tr>
<tr>
<td>UPDRS III</td>
<td>IL, ipsilateral to initial motor symptoms</td>
<td>Caudate nucleus</td>
<td>$-0.148$</td>
<td>$-0.645^a$</td>
</tr>
<tr>
<td></td>
<td>CL, contralateral to initial motor symptoms</td>
<td>Putamen</td>
<td>$-0.455$</td>
<td>$-0.794^a$</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Posterior putamen</td>
<td>$-0.235$</td>
<td>$-0.647^a$</td>
</tr>
</tbody>
</table>

CL, contralateral to initial motor symptoms; FDOPA, $[^{18}\text{F}]\text{fluoro-L-dopa}$; FMT, $[^{18}\text{F}]\text{fluoro-m-tyrosine}$; IL, ipsilateral to initial motor symptoms.

$^a$ Partial correlation coefficients (controlled for age) $> 0.6$ are significant (2-tailed $t$ statistic, $P < .05$).